拉米夫定治疗肺结核合并慢乙肝患者的临床疗效研究

Research on the therapeutic effect of lamivudine in treatment of pulmonary tuber culosis complicated with hepatitis B

目的探讨拉米夫定治疗肺结核合并慢性乙肝的临床疗效。方法将128例肺结核合并慢乙肝患者随机分为对照组与观察组,对照组患者接受常规抗结核及护肝治疗,观察组患者同时接受拉米夫定口服治疗。治疗3个月后评估2组的疗效。结果观察组患者痰菌阴转率及病灶显吸率显著优于对照组(P<0.05);观察组患者肝功能损伤发生率显著低于对照组(P<0.05);与对照组比较,观察组肝功能指标ALT、AST、TBIL及乙肝病毒复制指标HBV-DNA水平显著降低(P<0.05)。结论拉米夫定治疗肺结核合并慢乙肝疗效显著,可显著减少肝功能损害,并快速抑制乙肝病毒复制。

Objective To explore the effect of lamivudine in treatment of pulmonary tuber eulosis complicated with hepatitis B. Methods A total of 128 patients with pulmonary tuber culosis complicated with hepatitis B were randomly divided into control group and experiment group. The control group was given routine and anti-TB treatment. Meanwhile, the experiment group received oral lamivudine therapy. Clinical effects were evaluated 3 months after treatment. Results The sputum negative conversion rates and X-ray resorption rates in experiment group were superior to those in the control group （ P 〈 0.05）. The occurrence of liver dysfunction in experiment group were much lower than that in the control group （P 〈 0.05）. Compared with the control group, ALT, AST, TBIL and HBV-DNA level greatly decreased （P 〈 0.05）. Conclusion Lamivudine for pulmonary tuber culosis complicated with hepatitis B greatly improves the clinical effect, de- creases the liver dysfunction and rapidly inhibits the HBV replication.